CJC-1295 with DAC: Long‑Lasting Growth, Long‑Lasting You.
CJC‑1295 with DAC Peptide Therapy – Long‑Acting Growth Hormone Stimulation
Introduction
CJC‑1295 is a synthetic growth hormone–releasing hormone (GHRH) analogue. By binding to the same receptors that natural GHRH uses, it tells the pituitary gland to release more growth hormone (GH), which in turn increases insulin‑like growth factor‑1 (IGF‑1). Two formulations are available:
-
CJC‑1295 (without DAC) – also called Mod GRF (1‑29); it has a short half‑life (~30 min–2 h) and produces physiologic, pulsatile GH release. This version is often paired with other peptides (e.g., Ipamorelin) to amplify pulses.
-
CJC‑1295 with DAC – contains a Drug Affinity Complex (DAC) that binds to albumin in the blood. This binding dramatically extends the peptide’s half‑life to six–eight days, allowing once‑weekly injections. The trade‑off is continuous GH stimulation, which may increase side‑effect risk.
CJC‑1295 was initially developed for clinical use in growth hormone deficiency. It remains an investigational therapy in the United States but is prescribed off‑label in age‑management and performance medicine programs.
How CJC-1295 with DAC Works
CJC‑1295 with DAC mimics endogenous GHRH but adds a Drug Affinity Complex that prolongs its activity. When administered subcutaneously:
-
DAC binding – the DAC attaches to albumin, protecting the peptide from degradation and slowing its clearance.
-
Prolonged GH and IGF‑1 release – the extended half‑life means the pituitary receives prolonged GHRH‑like signals, leading to sustained GH and IGF‑1 elevations.
-
Downstream effects – increased GH and IGF‑1 can enhance protein synthesis, fat metabolism, collagen production and cellular repair.
This continuous stimulation is convenient (weekly dosing) but may not mimic natural pulsatile GH rhythms, which is why some clinics reserve the DAC version for specific cases.
Research and Evidence of CJC-1295 with DAC
Most human studies of CJC‑1295 have evaluated the non‑DAC version or combined it with ghrelin agonists (Ipamorelin). However, the DAC variant’s extended half‑life has been shown to increase GH and IGF‑1 for several days. Key findings include:
-
Growth hormone secretion: Early trials of CJC‑1295 (with DAC) demonstrated significant increases in GH and IGF‑1 lasting several days after a single dose.
-
Body composition: Growth hormone secretagogues (including CJC‑1295 and Ipamorelin) have been associated with improvements in lean mass and reductions in body fat.
-
Synergy with Ipamorelin: Ipamorelin is a ghrelin receptor agonist that produces a rapid GH pulse without affecting cortisol. Combining Ipamorelin with CJC‑1295 leverages both the immediate and sustained GH release.
-
Clinical programs: Clinics report benefits such as improved sleep, recovery, muscle growth and fat loss, but rigorous placebo‑controlled studies are limited. In many clinics, CJC‑1295 w/ DAC is considered second‑line because physiologic pulsatile GH release is preferable.
Benefits and Therapeutic Applications of CJC-1295 with DAC
CJC‑1295 with DAC therapy may provide the following benefits when used under medical supervision:
-
Lean muscle growth and strength: Sustained GH elevation can enhance protein synthesis and muscle hypertrophy.
-
Fat loss and improved body composition: Elevated GH and IGF‑1 promote lipolysis and reduce visceral fat; this is often amplified when combined with Ipamorelin or lifestyle interventions.
-
Enhanced recovery and healing: GH increases collagen synthesis and accelerates tissue repair, benefiting athletes or those healing from injuries.
-
Better sleep quality: Growth hormone peaks during slow‑wave sleep; higher GH levels may improve sleep depth and recovery.
-
Skin and collagen support: GH and IGF‑1 stimulate fibroblasts, potentially improving skin elasticity and reducing wrinkles.
Evidence Strength of CJC-1295 with DAC
While anecdotal reports and clinic data are promising, high‑quality trials of CJC‑1295 with DAC in healthy adults are limited. Patients should consider therapy within a comprehensive lifestyle program (nutrition, exercise, sleep) and under the guidance of experienced practitioners.
Side‑Effects and Safety Considerations of CJC-1295 with DAC
CJC‑1295 with DAC is generally well tolerated but carries risks, particularly because of its prolonged activity:
-
Flushing and injection‑site reactions – redness or warmth may occur shortly after injection.
-
Water retention and edema – sustained GH elevation can cause water retention, swelling or bloating.
-
Numbness or tingling – some individuals report paresthesias in hands or feet.
-
Mood changes and headaches – similar to other GH secretagogues, CJC‑1295 may cause headaches, vertigo, anxiety or irritability.
-
Hypertension and insulin resistance – long‑term GH excess can contribute to high blood pressure or dysregulated glucose metabolism.
-
Potential cancer risk – elevated IGF‑1 may theoretically promote growth of existing tumors. Patients with active cancer or history of malignancy should avoid GH secretagogues.
Because the DAC version remains active for up to eight days, any adverse effects may persist longer than with short‑acting peptides. Individuals with diabetes, cardiovascular disease, or active cancer should avoid CJC‑1295 with DAC and consider alternative therapies under physician guidance.
CJC-1295 with DAC vs. Without DAC – Comparison
| Feature | CJC‑1295 (no DAC) | CJC‑1295 with DAC | Notes |
|---|---|---|---|
| Half‑life | ~30 minutes–2 hours | ~6–8 days | Longer half‑life allows weekly dosing but keeps GH elevated continuously. |
| Dosing frequency | Daily or 5 days/week | Once weekly | Fewer injections with DAC; harder to titrate or stop if side‑effects occur. |
| GH release pattern | Pulsatile – mimics natural rhythms | Sustained – continuous GH elevation | Pulsatile release may reduce receptor desensitization and side‑effect risk. |
| Side‑effect profile | Generally lower; easier to adjust dose or discontinue | Higher risk of water retention, numbness, flushing, hypertension | Side‑effects last longer due to extended half‑life. |
| Clinical preference | Often used with Ipamorelin for synergistic GH pulses | Considered second‑line; some clinics recommend avoiding DAC due to safety concerns | Patients seeking convenience must weigh benefits vs. risks. |
Who Is an Ideal Candidate for CJC-1295 with DAC?
CJC‑1295 with DAC may suit individuals who:
-
Want weekly dosing and are comfortable with sustained GH elevation.
-
Are middle‑aged or older with signs of growth hormone deficiency (fatigue, poor sleep, decreased muscle mass) and have no contraindications.
-
Require additional recovery support (e.g., athletes healing from injury) and have tried short‑acting peptides with inadequate results.
However, CJC‑1295 with DAC is not recommended for patients with active cancer, uncontrolled hypertension, untreated diabetes, pregnancy or breastfeeding, or those with cardiovascular disease or a family history of hormone‑responsive tumors.
Administration and Dosing of CJC-1295 with DAC
-
Route: Subcutaneous injection into the abdomen or thigh. Use sterile technique; rotate sites to minimize irritation.
-
Typical dose: 30–60 µg per kg body weight once weekly. Exact dosing depends on age, weight, goals and clinical response.
-
Duration: Therapy duration varies; common programs last 12 weeks with re‑assessment.
-
Combination therapy: Many clinicians pair CJC‑1295 with DAC with Ipamorelin or other peptides to maximize benefits while mitigating side‑effects. Discuss options with your provider.
Program & What’s Included (Desert Mobile Medical)
Our concierge telemedicine program for CJC‑1295 with DAC includes:
-
Initial telehealth consultation with a physician to review medical history, goals and contraindications.
-
Comprehensive lab testing to assess hormone levels, metabolic markers and health status.
-
Customized dosing protocol with once‑weekly injections and instructions for safe administration.
-
Ongoing medical oversight via secure patient portal and scheduled follow‑ups.
-
Lifestyle guidance on nutrition, sleep hygiene, stress management and exercise to enhance GH responsiveness.
-
Medication shipped discreetly to your home with all supplies.
Pricing: $449 per month, including telemedicine visits, medication, dosing supplies and physician support (membership discounts may apply).
Expected Benefits Timeline of CJC-1295 with DAC
| Week | What to Expect |
|---|---|
| Weeks 1–2 | Learn injection technique; subtle improvements in sleep and wellbeing. |
| Weeks 3–6 | Better recovery, more energy and motivation; possible mild water retention or flushing. |
| Weeks 6–12 | Visible changes in body composition (leaner physique, decreased fat); improved skin tone and collagen. |
| Beyond 12 weeks | Continued improvements in strength and metabolism. Ongoing monitoring ensures safety and efficacy. |
Frequently Asked Questions
What does DAC mean?
DAC stands for Drug Affinity Complex—a molecular modification that enables the peptide to bind to albumin and remain active for six–eight days. This prolongs GH stimulation and allows weekly injections but increases the risk of sustained side‑effects.
How does CJC‑1295 differ from growth hormone?
CJC‑1295 stimulates your own pituitary to release more GH, whereas recombinant human growth hormone (rhGH) delivers exogenous GH. CJC‑1295 therefore produces more physiologic GH and IGF‑1 patterns and may carry fewer risks of acromegaly or endocrine disruption. The DAC version still elevates GH continuously for several days.
Can I combine CJC‑1295 with DAC with other peptides?
Yes. Many clinicians pair it with Ipamorelin, a ghrelin receptor agonist that produces immediate GH pulses without increasing cortisol. This combination provides both fast‑acting and sustained GH release, enhancing fat loss and muscle growth. However, due to the long half‑life of DAC, side‑effects may still persist between doses.
Who should avoid CJC‑1295 with DAC therapy?
Individuals with cancer, uncontrolled hypertension, untreated diabetes, pregnancy, breastfeeding or a history of hormone‑responsive tumors should avoid this therapy. Those with cardiovascular disease or at high risk of metabolic disorders should discuss safer alternatives like short‑acting CJC‑1295 or Tesamorelin.
Is CJC‑1295 with DAC approved by the FDA?
No. CJC‑1295 (with or without DAC) is not FDA‑approved for general medical use. It is prescribed off‑label in some clinics for research or anti‑aging purposes. Patients should be fully informed of the experimental nature and potential risks.
This content is for educational purposes only and should not be interpreted as medical advice. Always consult a qualified healthcare provider before beginning any new therapy.
About the Author
-
Dr. Paresh Goel, MD – Board‑certified concierge physician with special interests in hormone optimization, longevity medicine and regenerative therapies. Dr. Goel has overseen hundreds of peptide therapy patients and ensures ethical, evidence‑based care.
-
Dr. Aalia Avelin, NMD – Integrative physician focused on preventive medicine and holistic health. Dr. Avelin medically reviews all content for accuracy and alignment with current research.
